Role of HDL-C as a cardiovascular risk factor: clinical relevance of pitavastatin

References

• WHO. Cardiovascular diseases. World Health Organisation (2010).
   Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345–1361 (2011).
   Google Scholar
• Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society. Atherosclerosis 217S, S1–S44 (2011).
   Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364, 937–952 (2004).
   Google Scholar
• O’Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet 376, 112–123 (2010).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366, 1267–1278 (2005).
   Google Scholar
• Wolfram RM, Brewer HB, Xue Z et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am. J. Cardiol. 98, 711–717 (2006).
   Google Scholar
• Libby P, Theroux P. Pathphysiology of coronary artery disease. Circulation 111, 3481–3488 (2005).
   Google Scholar
• Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009).
   Google Scholar
• Sachdeva A, Cannon CP, Deedwania PC et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am. Heart J. 157, 111–117 (2009).
   Google Scholar
• Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). Br. Med. J. 316, 823–828 (1998).
   Google Scholar
• Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk In Communities (ARIC) study, 1987–1993. Am. J. Epidemiol. 146, 483–494 (1997).
   Google Scholar
• Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342–374 (2006).
   Google Scholar
• Heinecke JW. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J. Clin. Lipidol. 4, 371–375 (2010).
   Google Scholar
• Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J. Atheroscler. Thromb. 17, 436–451 (2010).
   Google Scholar
• Miyares MA. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann. Pharmacother. 45, 84–94 (2011).
   Google Scholar
• Toth PP. CETP inhibition: does the future look promising? Curr. Cardiol. Rep. 13(6), 559–565 (2011).
   Google Scholar
• Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 21, 312–318 (2010).
   Google Scholar
• Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127–135 (2011).
   Google Scholar
• Santos RD, Schaefer EJ, Asztalos BF et al. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J. Lipid Res. 49, 349–357 (2008).
   Google Scholar
• Huang R, Silva RA, Jerome WG et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol. 18, 416–422 (2011).
   Google Scholar
• Barter PJ, Gunnar Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J. Lipid Res. 51, 1546–1553 (2010).
   Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297, 499–508 (2007).
   Google Scholar
• Ong DS, Anzinger JJ, Leyva FJ, Rubin N, Addadi L, Kruth HS. Extracellular cholesterol-rich microdomains generated by human macrophages and their potential function in reverse cholesterol transport. J. Lipid Res. 51, 2303–2313 (2010).
   Google Scholar
• Tall A. Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk. J. Clin. Lipidol. 4, 389–393 (2010).
   Google Scholar
• Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin. Lipidol. 4, 291–302 (2009).
   Google Scholar
• Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr. Med. Res. Opin. 25, 2755–2764 (2009).
   Google Scholar
• Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210, 202–208 (2010).
   Google Scholar
• Hounslow N, Budinski D, Eriksson M. Pitavastatin 4 mg shows comparable LDL-cholesterol and superior triglyceride reduction to simvastatin 40 mg in high-risk primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis Suppl. 11(3), 3–7 (2010).
   Google Scholar
• Stender S, Hounslow N. Robust efficacy of pitavastatin and comparable safety of pravastatin. Atherosclerosis Suppl. 10(2), 770 (2009).
   Google Scholar
• Yokote K, Bujo H, Hanaoka H et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 201, 345–352 (2008).
   Google Scholar
• Sasaki J, Ikeda Y, Kuribayashi T et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin. Ther. 30, 1089–1101 (2008).
   Google Scholar
• Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J. Atheroscler. Thromb. 16, 654–661 (2009).
   Google Scholar
• Maejima T, Yamazaki H, Aoki T et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem. Biophys. Res. Commun. 324, 835–839 (2004).
   Google Scholar
• Kontush A, Guérin M, Chapman MJ. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat. Clin. Pract. Cardiovasc. Med. 5, 329–336 (2008).
   Google Scholar
• Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8, 222–232 (2011).
   Google Scholar
• Maruyama T, Takada M, Nishibori Y et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ. J. 75, 1951–1959 (2011).
   Google Scholar
• Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv. Ther. 28, 799–810 (2011).
   Google Scholar